Contact Information: Contact: Rick Rountree SCYNEXIS 919-878-1144 Kelle Straw Merial 678-638-3690
SCYNEXIS Receives Merial Research Collaboration Milestone Payment
| Source: SCYNEXIS, INC.
RESEARCH TRIANGLE PARK, NC--(Marketwire - December 13, 2007) - SCYNEXIS, Inc. announced today
that it has earned a payment for meeting certain milestones in its
multi-year research collaboration with Merial Limited, which began in 2005.
SCYNEXIS, a premier drug discovery and development company, focuses
considerable medicinal chemistry, advanced biological screening,
bioanalytical and ADMET efforts towards Merial's animal health discovery
efforts.
"Merial is excited about the continued success of our pharmaceutical
discovery program and by the opportunity to continue working with SCYNEXIS
to conduct further research regarding novel compounds that will be designed
specifically to address animal health needs," said Dr. Peter Hanson, Head
of Pharmaceutical R&D, of Merial.
"SCYNEXIS is pleased to have reached an important milestone in the
discovery of innovative animal health solutions with our valued partner
Merial," said SCYNEXIS President and CEO Dr. Yves Ribeill. "The achievement
of this milestone demonstrates SCYNEXIS' ability to provide unique,
proprietary technologies and expertise to accelerate the discovery of
important pharmaceuticals."
About Merial
Merial is a world-leading, innovation-driven animal health company,
providing a comprehensive range of products to enhance the health,
well-being and performance of a wide range of animals. Merial employs
approximately 5,000 people and operates in more than 150 countries
worldwide. Its 2006 sales were nearly $2.2 billion. Merial Limited is a
joint venture between Merck & Co., Inc. and sanofi-aventis. For more
information, please see www.merial.com.
About SCYNEXIS
SCYNEXIS is a premier drug discovery and development company headquartered
in Research Triangle Park, North Carolina. SCYNEXIS' mission is to be the
leader in delivering effective and innovative drug pipeline solutions to
its pharmaceutical partners.
SCYNEXIS research teams integrate medicinal chemistry, advanced biological
screening, computational chemistry, bioanalysis and analytical chemistry
and use powerful, proprietary technologies such as the HEOS® Software
Suite, MEDCHEM-FACTORY® and KIT™ Kinase Inhibitor Technology to
advance molecules to candidate selection. SCYNEXIS development teams have
been tailored to be especially effective in moving customer projects from
the discovery phase to the clinic. SCYNEXIS process chemistry and
bioanalytical departments operate under current GMP/GLP guidelines and have
a strong track record of success. www.scynexis.com
®HEOS and MEDCHEM-FACTORY are registered trademarks of SCYNEXIS, Inc. and
™KIT Kinase Inhibitor Technology is a trademark of SCYNEXIS, Inc.